{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:35:50Z","timestamp":1780050950894,"version":"3.53.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities","award":["No. 2022AH010071"],"award-info":[{"award-number":["No. 2022AH010071"]}]},{"name":"the Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities","award":["No. 2022AH010071"],"award-info":[{"award-number":["No. 2022AH010071"]}]},{"name":"the Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities","award":["No. 2022AH010071"],"award-info":[{"award-number":["No. 2022AH010071"]}]},{"name":"the Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities","award":["No. 2022AH010071"],"award-info":[{"award-number":["No. 2022AH010071"]}]},{"name":"the Health Committee of Anhui Province, China","award":["No. AHWJ2023BAc10007"],"award-info":[{"award-number":["No. AHWJ2023BAc10007"]}]},{"name":"the Health Committee of Anhui Province, China","award":["No. AHWJ2023BAc10007"],"award-info":[{"award-number":["No. AHWJ2023BAc10007"]}]},{"name":"the Health Committee of Anhui Province, China","award":["No. AHWJ2023BAc10007"],"award-info":[{"award-number":["No. AHWJ2023BAc10007"]}]},{"name":"the Health Committee of Anhui Province, China","award":["No. AHWJ2023BAc10007"],"award-info":[{"award-number":["No. AHWJ2023BAc10007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34515-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:08:09Z","timestamp":1767416889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between platelet-to-lymphocyte ratio and high risk for prostate cancer among middle-aged and older US men"],"prefix":"10.1038","volume":"16","author":[{"given":"Yifan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyue","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"34515_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75 (1), 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"34515_CR2","doi-asserted-by":"publisher","first-page":"e237504","DOI":"10.1001\/jamanetworkopen.2023.7504","volume":"6","author":"S Kalavacherla","year":"2023","unstructured":"Kalavacherla, S. et al. Low-value prostate-specific antigen screening in older males. JAMA Netw. Open. 6 (4), e237504 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"34515_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40644-023-00562-x","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. 68)Ga-PSMA PET\/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA Gray zone. Cancer Imaging. 23 (1), 81 (2023).","journal-title":"Cancer Imaging"},{"issue":"4","key":"34515_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JU.0000000000003603","volume":"210","author":"K Yim","year":"2023","unstructured":"Yim, K. et al. Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial. J. Urol. 210 (4), 630\u2013638 (2023).","journal-title":"J. Urol."},{"issue":"9255","key":"34515_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: back to virchow? Lancet 357 (9255), 539\u2013545 (2001).","journal-title":"Lancet"},{"key":"34515_CR6","doi-asserted-by":"crossref","unstructured":"Lee, H. M., Lee, H. J. & Chang, J. E. Inflammatory cytokine: an attractive target for cancer treatment. Biomedicines. ;10(9) (2022).","DOI":"10.3390\/biomedicines10092116"},{"key":"34515_CR7","doi-asserted-by":"publisher","first-page":"1040163","DOI":"10.3389\/fphar.2022.1040163","volume":"13","author":"Y Wen","year":"2022","unstructured":"Wen, Y. et al. Chronic inflammation, cancer development and immunotherapy. Front. Pharmacol. 13, 1040163 (2022).","journal-title":"Front. Pharmacol."},{"issue":"7203","key":"34515_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454 (7203), 436\u2013444 (2008).","journal-title":"Nature"},{"issue":"4","key":"34515_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrc2090","volume":"7","author":"AM De Marzo","year":"2007","unstructured":"De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 7 (4), 256\u2013269 (2007).","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"34515_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"JS de Bono","year":"2020","unstructured":"de Bono, J. S. et al. Prostate carcinogenesis: inflammatory storms. Nat. Rev. Cancer. 20 (8), 455\u2013469 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"34515_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijsu.2018.11.020","volume":"60","author":"J Guo","year":"2018","unstructured":"Guo, J. et al. Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis. Int. J. Surg. 60, 216\u2013223 (2018).","journal-title":"Int. J. Surg."},{"key":"34515_CR12","unstructured":"Curtin, L. R. et al. National health and nutrition examination survey: sample design, 2007\u20132010. Vital Health Stat. 2(160), 1\u201323 (2013)."},{"issue":"19","key":"34515_CR13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","volume":"279","author":"WJ Catalona","year":"1998","unstructured":"Catalona, W. J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (19), 1542\u20131547 (1998).","journal-title":"JAMA"},{"issue":"3","key":"34515_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses, K. A. et al. NCCN Guidelines(R) insights: prostate cancer early Detection, version 1.2023. J. Natl. Compr. Cancer Netw. 21 (3), 236\u2013246 (2023).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"34515_CR15","doi-asserted-by":"publisher","first-page":"1441271","DOI":"10.3389\/fonc.2024.1441271","volume":"14","author":"R He","year":"2024","unstructured":"He, R., Ye, Y., Zhu, Q. & Xie, C. Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. Elderly: evidence from NHANES 2001\u20132010. Front. Oncol. 14, 1441271 (2024).","journal-title":"Front. Oncol."},{"issue":"6","key":"34515_CR16","doi-asserted-by":"publisher","first-page":"e1327","DOI":"10.1002\/iid3.1327","volume":"12","author":"W Yao","year":"2024","unstructured":"Yao, W. et al. Associations of systemic immune-inflammation index with high risk for prostate cancer in middle-aged and older US males: A population-based study. Immun. Inflamm. Dis. 12 (6), e1327 (2024).","journal-title":"Immun. Inflamm. Dis."},{"issue":"4","key":"34515_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.pcan.4500232","volume":"1","author":"AW Partin","year":"1998","unstructured":"Partin, A. W. et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis. 1 (4), 197\u2013203 (1998).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"15","key":"34515_CR18","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.7314\/APJCP.2015.16.15.6407","volume":"16","author":"OH Yuksel","year":"2015","unstructured":"Yuksel, O. H., Urkmez, A., Akan, S., Yldirim, C. & Verit, A. Predictive value of the platelet-to-lymphocyte ratio in diagnosis of prostate cancer. Asian Pac. J. Cancer Prev. 16 (15), 6407\u20136412 (2015).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"7","key":"34515_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3889\/oamjms.2019.252","volume":"7","author":"KP Adhyatma","year":"2019","unstructured":"Adhyatma, K. P. & Warli, S. M. Diagnostic value of platelet-to-lymphocyte ratio in prostate cancer. Open. Access. Maced J. Med. Sci. 7 (7), 1093\u20131096 (2019).","journal-title":"Open. Access. Maced J. Med. Sci."},{"key":"34515_CR20","doi-asserted-by":"crossref","unstructured":"Zhang, J. Y., Ge, P., Zhang, P. Y., Zhao, M. & Ren, L. Role of neutrophil to lymphocyte ratio or platelet to lymphocyte ratio in prediction of bone metastasis of prostate cancer. Clin. Lab 65(5) (2019).","DOI":"10.7754\/Clin.Lab.2018.181040"},{"issue":"40","key":"34515_CR21","doi-asserted-by":"publisher","first-page":"e12504","DOI":"10.1097\/MD.0000000000012504","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Med. (Baltim). 97 (40), e12504 (2018).","journal-title":"Med. (Baltim)."},{"issue":"8","key":"34515_CR22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/ccr3.2288","volume":"7","author":"OE Yausep","year":"2019","unstructured":"Yausep, O. E. et al. Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: an evidence-based case report and review of literature. Clin. Case Rep. 7 (8), 1585\u20131590 (2019).","journal-title":"Clin. Case Rep."},{"issue":"47","key":"34515_CR23","doi-asserted-by":"publisher","first-page":"e35843","DOI":"10.1097\/MD.0000000000035843","volume":"102","author":"E Sahin","year":"2023","unstructured":"Sahin, E. et al. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617. Med. (Baltim). 102 (47), e35843 (2023).","journal-title":"Med. (Baltim)."},{"key":"34515_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12885-016-2363-5","volume":"16","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer. 16, 329 (2016).","journal-title":"BMC Cancer"},{"issue":"1","key":"34515_CR25","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.1038\/s41598-021-93637-3","volume":"11","author":"JW Lee","year":"2021","unstructured":"Lee, J. W., Jeong, H., Son, H. & Cho, M. C. Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study. Sci. Rep. 11 (1), 14240 (2021).","journal-title":"Sci. Rep."},{"key":"34515_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omto.2023.04.007","volume":"29","author":"M Lin","year":"2023","unstructured":"Lin, M., Sun, X. & Lv, L. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Mol. Ther. Oncolytics. 29, 91\u2013106 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"34515_CR27","doi-asserted-by":"publisher","first-page":"640578","DOI":"10.3389\/fimmu.2021.640578","volume":"12","author":"L Schmied","year":"2021","unstructured":"Schmied, L., Hoglund, P. & Meinke, S. Platelet-mediated protection of cancer cells from immune surveillance-possible implications for cancer immunotherapy. Front. Immunol. 12, 640578 (2021).","journal-title":"Front. Immunol."},{"issue":"3","key":"34515_CR28","first-page":"20240084","volume":"5","author":"Q Lu","year":"2025","unstructured":"Lu, Q. et al. Surface-Anchored Ticagrelor gelatin Nanoparticles-Platelets system for enhanced Anti-PD-L1 therapy response and boosted chemotherapeutic efficacy of nanomedicines. Explor. (Beijing). 5 (3), 20240084 (2025).","journal-title":"Explor. (Beijing)"},{"key":"34515_CR29","doi-asserted-by":"crossref","unstructured":"Metelli, A. et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-beta. Sci. Transl. Med. 12(525) (2020).","DOI":"10.1126\/scitranslmed.aay4860"},{"key":"34515_CR30","doi-asserted-by":"publisher","first-page":"1491099","DOI":"10.3389\/fonc.2024.1491099","volume":"14","author":"J Xu","year":"2024","unstructured":"Xu, J. & Tang, Z. Progress on angiogenic and antiangiogenic agents in the tumor microenvironment. Front. Oncol. 14, 1491099 (2024).","journal-title":"Front. Oncol."},{"issue":"8","key":"34515_CR31","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/ijc.24016","volume":"124","author":"O Dashevsky","year":"2009","unstructured":"Dashevsky, O., Varon, D. & Brill, A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int. J. Cancer. 124 (8), 1773\u20131777 (2009).","journal-title":"Int. J. Cancer"},{"key":"34515_CR32","doi-asserted-by":"crossref","unstructured":"Mao, F. et al. Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients. Int. Immunopharmacol. 113(Pt A), 109287 (2022).","DOI":"10.1016\/j.intimp.2022.109287"},{"issue":"1","key":"34515_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s42003-023-04812-3","volume":"6","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice. Commun. Biol. 6 (1), 447 (2023).","journal-title":"Commun. Biol."},{"issue":"1","key":"34515_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"Gooden, M. J., de Bock, G. H., Leffers, N., Daemen, T. & Nijman, H. W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer. 105 (1), 93\u2013103 (2011).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"34515_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2), 137\u2013148 (2004).","journal-title":"Immunity"},{"issue":"6","key":"34515_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40279-016-0648-0","volume":"47","author":"RJ Shephard","year":"2017","unstructured":"Shephard, R. J. Physical activity and prostate cancer: an updated review. Sports Med. 47 (6), 1055\u20131073 (2017).","journal-title":"Sports Med."},{"key":"34515_CR37","doi-asserted-by":"crossref","unstructured":"Pernar, C. H., Ebot, E. M., Wilson, K. M. & Mucci, L. A. The epidemiology of prostate cancer. Cold Spring Harb Perspect. Med. ;8(12) (2018).","DOI":"10.1101\/cshperspect.a030361"},{"issue":"1","key":"34515_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2019.09.007","volume":"31","author":"JM Genkinger","year":"2020","unstructured":"Genkinger, J. M. et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in the pooling project of prospective studies of diet and cancer. Ann. Oncol. 31 (1), 103\u2013114 (2020).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34515-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34515-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34515-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:23:55Z","timestamp":1769768635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34515-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34515-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The NHANES protocol was approved by the NCHS Ethics Review Committee, and all participants provided written informed consent. As this research involved secondary analysis of publicly available and de-identified data, further institutional review board approval was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"4291"}}